Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca, Marc; Nault, Patrice; Giugliano, Robert; Keech, Anthony; Pineda, Armando; Kanevsky, Estella; Kuder, Julia; Murphy, Sabina; Jukema, J.; Lewis, Basil; Tokgozoglu, SADBERK; Somaratne, Ransi; Sever, Peter; Pedersen, Terje; Sabatine, Marc

doi:10.1161/circulationaha.117.032235

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca M. P., Nault P., Giugliano R. P., Keech A. C., Pineda A. L., Kanevsky E., ...Daha Fazla

CIRCULATION, cilt.137, sa.4, ss.338-350, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 137 Sayı: 4
Basım Tarihi: 2018
Doi Numarası: 10.1161/circulationaha.117.032235
Dergi Adı: CIRCULATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.338-350
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). We investigated the efficacy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on major adverse limb events.